RxDoctor Payments Data

Swarna Byri, MD

Nephrology · Manteca, CANPI 1871731414

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 42 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$219
  • Baxter Healthcare$200
  • AstraZeneca$163
  • Amgen$114
  • Bard Peripheral Vascular, Inc.$95
  • Otsuka America Pharmaceutical, Inc.$78
  • plus $253 from 6 others

What the payments were for

  • Food & beverage$98388%
  • Education$13812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,122 in reported general payments places this provider in the 45th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$463,553
Medicare patients
616
Services billed
3,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan14$153,896
FarxigaDapagliflozin Propanediol158$105,036
VeltassaPatiromer Calcium Sorbitex95$89,647
JardianceEmpagliflozin80$53,450
LokelmaSodium Zirconium Cyclosilicate86$50,067
AuryxiaFerric Citrate20$43,338
VelphoroSucroferric Oxyhydroxide20$36,340
KerendiaFinerenone24$19,868
Calcium Acetate113$8,891
DapagliflozinDapagliflozin Propanediol16$7,933
Sevelamer Carbonate64$7,764
ProsolParenteral Amino Acid 20% No.133$5,735
Tacrolimus18$5,195
Mycophenolate Mofetil30$3,106
Potassium Citrate ErPotassium Citrate35$2,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$163$155,103244 claims
Akebia Therapeutics IncAuryxia$25$43,33820 claims
Fresenius USA Marketing, Inc.Velphoro$47$36,34020 claims
BayerKerendia$43$19,86824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,341 nephrology providers in California.

Other nephrology in Manteca

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →